Global Chronic Iron Overload Market, By Treatment Type (Iron Chelation Therapy, Surgery, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2029.
Chronic Iron Overload Market Analysis and Size
The global chronic iron overload market is expected to witness significant growth during the forecast period. The growing occurrence of pathologies related to iron overload, natural chelators may be essential alternatives to synthetic chelators and phlebotomy in managing iron overload, particularly in resource-poor countries. Sudden outbreak of the COVID-19 pandemic imposed stringent lockdown regulations globally, causing interruptions in import and export activities of global keloid treatment market.
Data Bridge Market Research analyses a growth rate in the global chronic iron overload market in the forecast period 2022-2029. The expected CAGR of global chronic iron overload market is tend to be around 5.70% in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
People with iron overload disorders absorb more iron than usual from food or supplements. It gets difficult for the body to excrete the iron fast enough. The body stores it in organ tissue, mainly in the liver, as well as the heart and the pancreas. There are numerous types of iron overload disorder. Hereditary hemochromatosis is a primary condition that has a genetic component. People can also have secondary hemochromatosis, which develops due to another disease or condition. This disease occurrence is increasing and important diagnostic procedures and treatments will increase the market's growth.
Chronic Iron Overload Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment Type (Iron Chelation Therapy, Surgery, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AstraZeneca (U.K.), CHIESI Farmaceutici S.p.A. (Italy), Apotex Inc. (Canada), Swedish Orphan Biovitrum AB (Sweden)
|
|
Market Opportunities
|
|
Global Chronic Iron Overload Market Dynamics
Drivers
- Technological Advancements
Glycocholic acid (GCA) is a type of biomarker for liver disorders, but till now, only few simple naked-eye detection methods have been accessible. A simple naked-eye visible approach for GCA detection was developed using this anti-GCA mAb and a modified red-colored bacterial strain. This approach of detecting GCA takes only a few minutes and requires no costly equipment. It is a quick, convenient, and direct approach for detecting GCA to diagnose the liver disorders. Thus, it boosts the market growth.
Opportunities
- Rising Healthcare Awareness
Health awareness amongst the population are increasing, leading to the huge production of drugs boost the market growth. The innovative launches in medications for the treatment of chronic iron overload are expected to prompt the market simultaneously. Different researchers are investing in launching the drugs that benefit the market. This creates more opportunities in the market.
- Recent Developments
Silence Therapeutics' primary RNAi drug in development aims to cure and reverse iron diseases, such as beta-thalassemia, myelodysplastic syndrome, and hemochromatosis, notably underdiagnosed and undertreated. It has been observed that target a protein named hepcidin, a critical iron balance regulator in the body, the company's technique could lower iron levels in the blood. So, it has amplified the demand for iron overload treatment.
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified personnel who are unable to perform these treatments could curb the growth of the global chronic iron overload market over a forecast period.
- Unavailability of Appropriate Treatments
To treat conditions that are rare, many a times, all treatments are not available, especially in under-developed countries. Severe patients needs to be treated with advanced techniques but at times, these are not available in the hospitals and clinics. Thus, it hampers the market growth.
This global chronic iron overload market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global chronic iron overload market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Chronic Iron Overload Market
The COVID-19 pandemic has severely impacted healthcare systems and the market. Iron deficiency is becoming more extensively recognized as a factor in COVID-19. COVID-19 symptoms, such as inflammation, hypercoagulation, hyperferritinemia, and immunological dysfunction, are similar to iron overload. Iron chelation can be used as an adjuvant therapy for treating COVID-19 patients. Iron chelators such as deferasirox, deferoxamine, and deferiprone, in addition to the naturally occurring iron chelator lactoferrin, may be beneficial in the fight against COVID-19. Iron chelators may be useful not only for iron isolation and inflammation reduction, but also for preventing the coronavirus from attaching to the receptors it uses to enter host cells. Furthermore, the pandemic is disrupting the supply chain, and many businesses will relocate to other geographic regions in the future to ensure that products remain available and to protect their supply chain. As a result, the COVID-19 pandemic has had an impact on the market.
Global Chronic Iron Overload Market Scope
The global chronic iron overload market is segmented on the basis of treatment type, route of administration, end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment Type
- Iron Chelation Therapy
- Surgery
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Chronic Iron Overload Market Regional Analysis/Insights
The global chronic iron overload market is analysed and market size insights and trends are provided by treatment type, route of administration,end-user, distribution channel as referenced above.
The major countries covered in the global chronic iron overload market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the market due to the increased incidence of chronic iron overload, high demand of targeted therapies and advanced healthcare facilities.
Asia-Pacific is considered to have the most lucrative period due to the increase awareness about the diseases and rapidly disposable income.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Chronic Iron Overload Market Share Analysis
The global chronic iron overload market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global chronic iron overload market.
Key players operating in the global chronic iron overload market include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- AstraZeneca (U.K.)
- CHIESI Farmaceutici S.p.A. (Italy)
- Apotex Inc. (Canada)
- Swedish Orphan Biovitrum AB (Sweden)
SKU-